Goldman Sachs Group Inc Xeris Biopharma Holdings, Inc. Transaction History

Goldman Sachs Group Inc

  • $780 Billion
  • Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,795,455 shares of XERS stock, worth $13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,795,455
Previous 2,271,486 20.96%
Holding current value
$13 Million
Previous $10.6 Million 37.11%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
SELL
$4.68 - $8.3 $2.23 Million - $3.95 Million
-476,031 Reduced 20.96%
1,795,455 $14.5 Million
Q2 2025

Aug 14, 2025
SELL
$3.95 - $5.16 $2.05 Million - $2.68 Million
-518,528 Reduced 18.59%
2,271,486 $10.6 Million
Q1 2025

May 09, 2025
BUY
$3.2 - $5.95 $3.84 Million - $7.14 Million
1,199,435 Added 75.41%
2,790,014 $15.3 Million
Q4 2024

Feb 11, 2025
BUY
$2.78 - $3.73 $2.1 Million - $2.81 Million
754,137 Added 90.16%
1,590,579 $5.39 Million
Q3 2024

Nov 14, 2024
BUY
$2.06 - $2.96 $1.07 Million - $1.54 Million
520,778 Added 164.98%
836,442 $2.38 Million
Q2 2024

Aug 13, 2024
BUY
$1.7 - $2.45 $109,167 - $157,329
64,216 Added 25.54%
315,664 $710,000
Q1 2024

May 15, 2024
SELL
$2.04 - $3.22 $14,771 - $23,316
-7,241 Reduced 2.8%
251,448 $555,000
Q4 2023

Feb 13, 2024
BUY
$1.47 - $2.36 $184,998 - $297,003
125,849 Added 94.74%
258,689 $607,000
Q3 2023

May 14, 2024
SELL
$1.8 - $2.69 $226,528 - $338,533
-125,849 Reduced 48.65%
132,840 $247,000
Q3 2023

Nov 14, 2023
SELL
$1.8 - $2.69 $164,343 - $245,602
-91,302 Reduced 40.73%
132,840 $247,000
Q2 2023

May 14, 2024
BUY
$1.82 - $2.98 $181,248 - $296,769
99,587 Added 79.95%
224,142 $587,000
Q2 2023

Aug 14, 2023
BUY
$1.82 - $2.98 $181,248 - $296,769
99,587 Added 79.95%
224,142 $587,000
Q1 2023

May 14, 2024
SELL
$1.03 - $1.63 $40,463 - $64,034
-39,285 Reduced 23.98%
124,555 $203,000
Q1 2023

May 11, 2023
SELL
$1.03 - $1.63 $40,463 - $64,034
-39,285 Reduced 23.98%
124,555 $203,000
Q4 2022

May 14, 2024
BUY
$1.14 - $1.65 $46,961 - $67,970
41,194 Added 33.59%
163,840 $217,000
Q4 2022

Feb 13, 2023
BUY
$1.14 - $1.65 $46,961 - $67,970
41,194 Added 33.59%
163,840 $217,000
Q3 2022

May 14, 2024
BUY
$1.37 - $1.93 $13,845 - $19,504
10,106 Added 8.98%
122,646 $191,000
Q3 2022

Nov 10, 2022
BUY
$1.37 - $1.93 $13,845 - $19,504
10,106 Added 8.98%
122,646 $0
Q2 2022

May 14, 2024
SELL
$1.48 - $2.64 $216,300 - $385,833
-146,149 Reduced 56.5%
112,540 $173,000
Q2 2022

Aug 15, 2022
SELL
$1.48 - $2.64 $906,818 - $1.62 Million
-612,715 Reduced 84.48%
112,540 $173,000
Q1 2022

May 16, 2022
BUY
$2.0 - $2.87 $995,128 - $1.43 Million
497,564 Added 218.53%
725,255 $1.86 Million
Q4 2021

Feb 14, 2022
BUY
$1.8 - $2.93 $409,843 - $667,134
227,691 New
227,691 $667,000

Others Institutions Holding XERS

# of Institutions
236
Shares Held
94.1M
Call Options Held
251K
Put Options Held
61.8K
View Full List

About Xeris Biopharma Holdings, Inc.

XERS Quotes by TradingView
  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $986M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email